Physician profile
William B Johnson
NPI 1295715969
$889.38
in general payments reported to CMS, 2019-2025
15 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.82 · 2020: $49.39 · 2021: $39.55 · 2022: $183 · 2023: $225 · 2024: $185 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $208.66 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $113.32 | 2023-2025 | |
| Glaxosmithkline, LLC. | $106.87 | 2019-2025 | Pediarix, Penmenvy, Bexsero |
| Ironshore Pharmaceuticals INC. | $91.16 | 2022-2024 | |
| Corium, LLC | $66.98 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $45.38 | 2022-2023 | Doc Band |
| Sanofi Pasteur INC. | $45.30 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $40.07 | 2022-2025 | Qelbree |
| Alk-Abello, INC | $39.99 | 2024 | Grastek, Odactra, Ragwitek |
| Verrica Pharmaceuticals INC. | $30.16 | 2023 | Ycanth |
| Phadia US INC. | $29.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.87 | 2021 | |
| Chiesi USA, INC. | $20.62 | 2020 | |
| Collegium Pharmaceutical, INC. | $18.77 | 2025 | Jornay Pm |
| Genentech USA, INC. | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.